Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Dual-Lineage IDLV–CRISPR/Cas9 Editing of MSCs and HSPCs Enhances GALNS-Mediated Cross-Correction in MPS IVA In Vitro

5 affiliations
  1. 1Department of Research, Nemours Children’s Hospital, 1600 Rockland Road, Wilmington, DE 19803, USA
  2. 2Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
  3. 3PuREC Co., Ltd., Izumo 693-8501, Japan
  4. 4Department of Life Science, Shimane University, Izumo 693-8501, Japan
  5. 5Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA

Abstract

Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), in which current therapies incompletely correct skeletal disease because enzyme delivery to avascular cartilage is limited. We developed a dual-lineage ex vivo gene-editing strategy combining murine hematopoietic stem/progenitor cells (mHSPCAAVS1) and rapidly expanding clonal human mesenchymal stem cells (REC-MSCs), using an integrase-defective lentiviral (IDLV) CRISPR/Cas9 platform designed to deliver a GALNS cassette to the AAVS1 safe-harbor locus. Nocodazole-mediated G2/M synchronization further increased GALNS output in HDR-competent conditions. Edited REC-MSCs showed supraphysiological GALNS production and secretion, and edited mHSPCAAVS1 reached approximately 13.9-fold wild-type activity; enhanced expression persisted at 30 days post-transduction. In non-contact transwell co-culture, edited REC-MSCs and edited mHSPCAAVS1 each increased GALNS activity in MPS IVA patient fibroblasts, and combined exposure produced the greatest correction, reducing lysosomal mass by ~36%, mono-sulfated keratan sulfate by ~54%, and mitochondrial superoxide toward wild-type levels at 30 days. Irradiated REC-MSC feeder layers supported 2.59-fold mHSPCAAVS1 expansion and a 1.96-fold higher proportion of EGFP-positive cells. Cross-correction was therefore achieved by each lineage and was greatest in combination, establishing a functional basis for in vivo evaluation of this dual-lineage strategy in MPS IVA.

Related

  1. BASELINE: a CRISPR base editing platform for mammalian-scale single-cell lineage tracing
    Evan Winter, Francesco E. Emiliani, Aidan Cook +2
    Nucleic Acids ResearchPeer-reviewedCC BY-NC14 citedMolecular biology & gene regulationOpenAlex
  2. Comparison of Prime Editing and CRISPR-Cas Mediated HDR in Correcting CFTR-F508del Mutation in Patient iPSC-Derived Airway Basal Cells
    Olga Volodina, Anna Demchenko, Ekaterina Kondrateva +8
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  3. Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines
    Chloe Timmins-Young, Marco Cordani, Elisa Giovannetti +4
    STAR ProtocolsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMCEurope PMC
  4. CRISPR/Cas9‐Mediated Correction of the SLC25A38 Mutation in a Patient With Sideroblastic Anemia
    Shokoufeh Yazdanparast, Hamid Galehdari, SaeidReza Khatami +2
    The journal of gene medicinePeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  5. LNP-mediated CRISPR gene editing of human vascular endothelial cells in 2D and 3D microfluidic cell culture systems
    Amalie Lykke Olsen, Camilla Blunk Vorsø Brandt, Rasmus Karred Larsen +11
    Molecular therapy. Nucleic acidsPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC
BibTeX
@article{nidhi2026duallineage,
  title = {{Dual-Lineage IDLV–CRISPR/Cas9 Editing of MSCs and HSPCs Enhances GALNS-Mediated Cross-Correction in MPS IVA In Vitro}},
  author = {Fnu Nidhi and Shaukat Khan and Takashi Suyama and Yumi Matsuzaki and Shunji Tomatsu},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210245},
  url = {https://www.mdpi.com/1422-0067/27/22/10245},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Dual-Lineage IDLV–CRISPR/Cas9 Editing of MSCs and HSPCs Enhances GALNS-Mediated Cross-Correction in MPS IVA In Vitro
AU  - Fnu Nidhi
AU  - Shaukat Khan
AU  - Takashi Suyama
AU  - Yumi Matsuzaki
AU  - Shunji Tomatsu
PY  - 2026
DA  - 2026/11/15
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210245
UR  - https://www.mdpi.com/1422-0067/27/22/10245
AB  - Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), in which current therapies incompletely correct skeletal disease because enzyme delivery to avascular cartilage is limited. We developed a dual-lineage ex vivo gene-editing strategy combining murine hematopoietic stem/progenitor cells (mHSPCAAVS1) and rapidly expanding clonal human mesenchymal stem cells (REC-MSCs), using an integrase-defective lentiviral (IDLV) CRISPR/Cas9 platform designed to deliver a GALNS cassette to the AAVS1 safe-harbor locus. Nocodazole-mediated G2/M synchronization further increased GALNS output in HDR-competent conditions. Edited REC-MSCs showed supraphysiological GALNS production and secretion, and edited mHSPCAAVS1 reached approximately 13.9-fold wild-type activity; enhanced expression persisted at 30 days post-transduction. In non-contact transwell co-culture, edited REC-MSCs and edited mHSPCAAVS1 each increased GALNS activity in MPS IVA patient fibroblasts, and combined exposure produced the greatest correction, reducing lysosomal mass by ~36%, mono-sulfated keratan sulfate by ~54%, and mitochondrial superoxide toward wild-type levels at 30 days. Irradiated REC-MSC feeder layers supported 2.59-fold mHSPCAAVS1 expansion and a 1.96-fold higher proportion of EGFP-positive cells. Cross-correction was therefore achieved by each lineage and was greatest in combination, establishing a functional basis for in vivo evaluation of this dual-lineage strategy in MPS IVA.
SN  - 1422-0067
ER  -